Selecta RussiaSite MapContact Us

A New Class of Immunotherapies 

Selecta is a clinical-stage biotechnology company developing novel drugs that use immune modulating nanomedicines to generate antigen-specific immune responses to prevent and treat disease. 

Our proprietary technology platform of Synthetic Vaccine Particles (SVP™) is a product engine for the durable and antigen-specific treatment of undesired immune responses. Our antigen-specific, tolerogenic SVPs can be applied in a variety of therapeutic areas with large unmet medical need, and we are strategically focused on three key applications: inhibition of immunogenicity for protein therapies, treatment of allergies, and treatment of autoimmune diseases.

Through proprietary products and collaborations with leading pharmaceutical companies and research organizations, we are building a pipeline of product candidates to address unmet medical needs in serious and chronic diseases.

Learn More blue_arrow

Selecta Biosciences to Webcast Presentation at  Needham & Company 14th Annual Healthcare Conference


Tech_Pioneers_2014  Profile red_arrow

  • December 23, 2014 – Selecta and Skolkovo Foundation Collaborate to Develop a Synthetic Vaccine Particle in the Field of Immuno-oncology Read More red_arrow
  • October 15, 2014 – Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes Read More red_arrow
  • October 15, 2014 – Selecta Announces More than $20 Million in Equity Funding Read More red_arrow
  • June 17, 2014 – Selecta Accelerates Immune Tolerance Therapeutics and Announces New Product Candidate, SEL-212, for Refractory and Tophaceous Gout Read More red_arrow
  • June 17, 2014 – Selecta Biosciences Enters Into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout Read More red_arrow
  • June 17, 2014 – Selecta Biosciences to Accelerate Program for Novel Dual Action Vaccine for Malaria with support from the Bill & Melinda Gates Foundation Read More red_arrow
  • December 9, 2013 – Successful Pre-clinical Study of SEL-201 As An Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy Read More red_arrow
  • December 9, 2013 – USPTO Allows First In a Series of Selecta Patents for Antigen-Specific Immune Tolerance Read More red_arrow
  • August 27, 2013 – Selecta Distinguished as World Economic Forum Technology Pioneer 2014 Read More red_arrow
  • September 6, 2011 Picture2 – FierceBiotech Names Selecta Biosciences a 2011 Fierce 15 Biotech.  Read More red_arrow


© 2015 Selecta Biosciences, Inc.  |  480 Arsenal St., Building One, Watertown, MA 02472  |  Phone: 617-923-1400  |   Fax: 617-924-3454  |  Email:
Privacy Policy  |  Web site designed and developed by RainCastle Communications, Inc.